These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 22924510)
1. Therapeutic strategies for the treatment of spinal muscular atrophy. Cherry JJ; Androphy EJ Future Med Chem; 2012 Sep; 4(13):1733-50. PubMed ID: 22924510 [TBL] [Abstract][Full Text] [Related]
2. Therapeutics development for spinal muscular atrophy. Sumner CJ NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261 [TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Grzeschik SM; Ganta M; Prior TW; Heavlin WD; Wang CH Ann Neurol; 2005 Aug; 58(2):194-202. PubMed ID: 16049920 [TBL] [Abstract][Full Text] [Related]
4. Spinal muscular atrophy: from gene to therapy. Wirth B; Brichta L; Hahnen E Semin Pediatr Neurol; 2006 Jun; 13(2):121-31. PubMed ID: 17027862 [TBL] [Abstract][Full Text] [Related]
5. Survival motor neuron SMN1 and SMN2 gene promoters: identical sequences and differential expression in neurons and non-neuronal cells. Boda B; Mas C; Giudicelli C; Nepote V; Guimiot F; Levacher B; Zvara A; Santha M; LeGall I; Simonneau M Eur J Hum Genet; 2004 Sep; 12(9):729-37. PubMed ID: 15162126 [TBL] [Abstract][Full Text] [Related]
6. Spinal muscular atrophy: state-of-the-art and therapeutic perspectives. Wirth B Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Jun; 3(2):87-95. PubMed ID: 12215230 [TBL] [Abstract][Full Text] [Related]
7. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Wirth B Hum Mutat; 2000; 15(3):228-37. PubMed ID: 10679938 [TBL] [Abstract][Full Text] [Related]
8. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. Thurmond J; Butchbach ME; Palomo M; Pease B; Rao M; Bedell L; Keyvan M; Pai G; Mishra R; Haraldsson M; Andresson T; Bragason G; Thosteinsdottir M; Bjornsson JM; Coovert DD; Burghes AH; Gurney ME; Singh J J Med Chem; 2008 Feb; 51(3):449-69. PubMed ID: 18205293 [TBL] [Abstract][Full Text] [Related]
10. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Brichta L; Hofmann Y; Hahnen E; Siebzehnrubl FA; Raschke H; Blumcke I; Eyupoglu IY; Wirth B Hum Mol Genet; 2003 Oct; 12(19):2481-9. PubMed ID: 12915451 [TBL] [Abstract][Full Text] [Related]
11. [Molecular genetic basis of proximal spinal muscular atrophy and experience in its pharmaceutical treatment]. Baranov VS; Kiselev AV; Vakharlovskiĭ VG; Zhelezniakova GIu; Komantsev VN; Malysheva OV; Glotov AS; Ivashchenko TE; Baranov AN Genetika; 2008 Oct; 44(10):1325-37. PubMed ID: 19062530 [TBL] [Abstract][Full Text] [Related]
12. Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy. Rindt H; Buckley DM; Vale SM; Krogman M; Rose FF; Garcia ML; Lorson CL Neuromuscul Disord; 2012 Mar; 22(3):277-85. PubMed ID: 22079083 [TBL] [Abstract][Full Text] [Related]
13. SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS. Veldink JH; Kalmijn S; Van der Hout AH; Lemmink HH; Groeneveld GJ; Lummen C; Scheffer H; Wokke JH; Van den Berg LH Neurology; 2005 Sep; 65(6):820-5. PubMed ID: 16093455 [TBL] [Abstract][Full Text] [Related]
14. Cellular and molecular approaches to motor neuron therapy in amyotrophic lateral sclerosis and spinal muscular atrophy. O'Connor DM; Boulis NM Neurosci Lett; 2012 Oct; 527(2):78-84. PubMed ID: 22579818 [TBL] [Abstract][Full Text] [Related]
15. Spinal muscular atrophy: from animal model to clinical trial. Zanoteli E; Maximino JR; Conti Reed U; Chadi G Funct Neurol; 2010; 25(2):73-9. PubMed ID: 20923604 [TBL] [Abstract][Full Text] [Related]
16. Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy. Sun Y; Grimmler M; Schwarzer V; Schoenen F; Fischer U; Wirth B Hum Mutat; 2005 Jan; 25(1):64-71. PubMed ID: 15580564 [TBL] [Abstract][Full Text] [Related]